Remedica
Sandeep Vijay has a diverse work experience spanning over multiple companies and roles. Sandeep currently holds the position of Head of Market Development & Strategy at Remedica, starting in April 2023. Previously, they worked as an Engagement Manager at IQVIA Middle East and Africa from September 2020 to April 2023. Prior to that, Sandeep held various managerial positions at Cipla Ltd. from 2013 to 2020, including Senior Manager - Commercial Excellence, Senior Manager - Corporate Strategy, and Manager - Commercial Analytics. Sandeep also gained experience at Novartis as a Manager, Sr. Forecasting Analyst, and Forecasting Analyst, where they developed new benchmarks, supported business cases, and utilized Monte-Carlo simulation for forecasting. Before that, Sandeep worked as an Associate Consultant at WNS and as an Analyst at SmartAnalyst.
Sandeep Vijay completed their Bachelor of Technology degree in Chemical Engineering at the Indian Institute of Technology, Delhi from 2003 to 2007. Sandeep later pursued a Master of Business Administration (MBA) in Business Administration and Management from SVKM's Narsee Monjee Institute of Management Studies (NMIMS) from 2018 to 2020.
This person is not in any offices
Remedica
Remedica, is a leading pharmaceutical company, with export activities in more than 160 countries. Originally founded in 1960 by Mr. Takis Pattichis, Remedica specialises in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. Furthermore, Remedica offers out-licensing opportunities and its product portfolio consists of Antineoplastic agents, Antivirals, Aromatase inhibitors, Antiinfectives, products for the nervous system, products for the cardiovascular system, dermatologicals, antimalarials, and has pipeline consisting of more Therapeutic Categories. Currently, Remedica has 5 state-of-the-art factories all of which have been routinely inspected and approved by the health authorities of several European Union Member States including Cyprus, Germany, and Denmark as well as those of United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA) and many more. Remedica invests in product development, in innovation and technology, and in human resources, and encourages the progress of science, education and health. Remedica’s Corporate Social Responsibility (CSR) commitment is built on its vision, strategies and mission. It is based on its core business, operating background, stakeholder’s outlooks and company’s culture. By providing safe, efficacious and high quality pharmaceuticals at affordable prices, Remedica has improved the health and saved the lives of millions of people who may otherwise have had to pay more or who may not have been in a position to afford a more expensive treatment. To meet this commitment the company implements management systems in its operations that accord with the requirements of its CSR standards. Remedica’s CSR is based on various parameters which include but are not limited to Environment, Human Resources, Society and Education.